<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02609386</url>
  </required_header>
  <id_info>
    <org_study_id>IRX-2 2015-A</org_study_id>
    <nct_id>NCT02609386</nct_id>
  </id_info>
  <brief_title>IRX-2 Regimen in Patients With Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity</brief_title>
  <acronym>INSPIRE</acronym>
  <official_title>A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRX Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRX Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a pre-operative regimen of the study drug,
      IRX-2, a human cell-derived biologic with multiple active cytokine components, plus a single
      dose of cyclophosphamide, followed by 21 days of indomethacin, zinc-containing
      multivitamins, and omeprazole is active in treatment of oral cavity cancer. The regimen is
      intended to stimulate an immune response against the cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the activity and safety of the IRX Regimen in participants with newly
      diagnosed, untreated, surgically resectable squamous cell cancer of the oral cavity.
      Participants will be randomly assigned to receive either Regimen 1: IRX-2 + cyclophosphamide
      + indomethacin + zinc + omeprazole, or Regimen 2: cyclophosphamide + indomethacin + zinc +
      omeprazole.

      The primary study hypothesis is that the Regimen 1 with IRX-2 prolongs event-free survival
      and overall survival when compared to Regimen 2 without IRX-2.

      Subjects will be randomized to either Regimen 1 or Regimen 2 on a 2:1 basis and treated
      prior to surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Event-Free Survival from baseline</measure>
    <time_frame>At each study visit after surgery: at 3,6,9,12,15,18, 21,24,30,36,42,48 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if the event-free survival (EFS) of subjects treated with Regimen 1 is longer than for subjects treated with Regimen 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Overall Survival from baseline</measure>
    <time_frame>At each study visit after surgery: at 3,6,9,12,15,18,21,24,30,36,42,48 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if OS of subjects treated with Regimen 1 is longer than for subjects treated with Regimen 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in safety from baseline in each Regimen using a pre-approved questionnaire (case report form)</measure>
    <time_frame>At each study visit after surgery: at 3,6,9,12,15,18,21,24,30,36,42,48 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Medical professional will assess according to pre-specified list for patient response, lab results, adverse events, etc. at pre-specified intervals. Pain to be assessed using NCI Criteria grade from the following: None, Mild, Moderate or Severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor size from baseline to surgery</measure>
    <time_frame>Measured at time of pre-screening and at time of surgery (approx. 6-7 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>CT/MRI scan measurement, in cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lymphocyte infiltrates in tumor comparing pre-treatment biopsy and surgical specimens</measure>
    <time_frame>Measured at time of pre-screening and at time of surgery (approx. 6-7 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Computerized counting of lymphocyte infiltration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Squamous Cell Carcinoma of the Oral Cavity</condition>
  <arm_group>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IRX Regimen with IRX-2, cyclophosphamide, indomethacin, zinc-containing multivitamin, and omeprazole as neoadjuvant and adjuvant therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Regimen 1 but without IRX-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IRX-2</intervention_name>
    <description>Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <other_name>Immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Method of Administration: Cyclophosphamide is administered once by IV</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>Method of Administration: Indomethacin is administered orally for 21 days.</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>NSAID</other_name>
    <other_name>Indocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc-containing multivitamin</intervention_name>
    <description>Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>Zinc</other_name>
    <other_name>Multi-vitamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Method of Administration: Omeprazole is administered orally for 21 days</description>
    <arm_group_label>Regimen 1</arm_group_label>
    <arm_group_label>Regimen 2</arm_group_label>
    <other_name>Proton pump inhibitor</other_name>
    <other_name>Prilosec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed (histology or cytology) Stage III or IVA squamous cell
             cancer of the oral cavity (excluding lip)

          2. Disease surgically resectable with curative intent

          3. Hematological function: hemoglobin &gt;9 g/dL; lymphocyte count &gt;500 x 109/mL;
             neutrophil count &gt;1500 x 109/mL; platelet count &gt;100,000 x 109/mL

          4. Hepatic function: serum albumin &gt;3.0 g/dL; aspartate aminotransferase (AST/SGOT) and
             alanine aminotransferase (ALT/SGPT) &lt;3x the upper limits of normal (ULN); alkaline
             phosphatase &lt;2x the ULN

          5. Prothrombin time (PT) and partial thromboplastin time (PTT) &lt; 1.4x the ULN

          6. Calculated creatinine clearance &gt; 50 mL/minute (Appendix 3)

          7. At least 18 years of age

          8. Willing and able to give informed consent and adhere to protocol therapy

          9. Karnofsky performance status (KPS) &gt;=80%

         10. Able and willing to use a medically acceptable form of pregnancy prevention

         11. Negative urine/serum pregnancy test, if applicable

        Exclusion Criteria:

          1. Prior surgery, radiation therapy, or chemotherapy other than biopsy or emergency
             procedure required for supportive care of this oral cavity cancer.

          2. Any medical contraindications or previous therapy that would preclude treatment with
             either IRX 2 Regimen 1 or 2 or the surgery, reconstruction or adjuvant therapy
             required to treat the oral tumor appropriately

          3. Clinical status of either subject or tumor such that administration of 21 day
             neoadjuvant IRX-2 Regimen 1 or 2 before surgery would be medically inappropriate

          4. Tumor of the oropharynx

          5. Other clinical issues that would make participation in this clinical trial
             inappropriate.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory T Wolf, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Hospitals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>IRX INSPIRE</last_name>
    <email>INSPIRE@IRXTherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85742</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Placencia</last_name>
      <email>CPlacencia@uacc.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Audrey Erman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arkansas For Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Allen</last_name>
      <email>KGAllen@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Emre Vural, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Tse</last_name>
      <email>tse_g@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Jorge Nieva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manjit Gill</last_name>
      <phone>650-721-6399</phone>
      <email>manjit.gill@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Kaplan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington DC VA Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa Karkera</last_name>
      <email>deepa.karkera@va.gov</email>
    </contact>
    <investigator>
      <last_name>Steven Krasnow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Kimbrough</last_name>
      <email>jidiaz0@uky.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Kenady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Schiavo</last_name>
      <email>nschiavo@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Moyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Treude</last_name>
      <email>kjtreude@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Persaud</last_name>
      <email>Cpersaud9@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Dennis Kraus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Kiplinger</last_name>
      <email>Felicia-kiplinger@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Greg Krempl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Toussaint</last_name>
      <phone>503-215-6512</phone>
      <email>Sandra.Toussaint@providence.org</email>
    </contact>
    <investigator>
      <last_name>Bryan Bell, MD DDS FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shadiya Moss</last_name>
      <email>shadiya.moss@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://irxtherapeutics.com/</url>
    <description>Sponsor's website</description>
  </link>
  <link>
    <url>http://InspireHNC.com</url>
    <description>INSPIRE Trial website</description>
  </link>
  <reference>
    <citation>Wolf GT, Fee WE Jr, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, Suen J, Kenady DE, Newman JG, Carroll WR, Gillespie MB, Freeman SM, Baltzer L, Kirkley TD, Brandwein HJ, Hadden JW. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011 Dec;33(12):1666-74. doi: 10.1002/hed.21660. Epub 2011 Jan 31.</citation>
    <PMID>21284052</PMID>
  </reference>
  <reference>
    <citation>Berinstein NL, Wolf GT, Naylor PH, Baltzer L, Egan JE, Brandwein HJ, Whiteside TL, Goldstein LC, El-Naggar A, Badoual C, Fridman WH, White JM, Hadden JW. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother. 2012 Jun;61(6):771-82. doi: 10.1007/s00262-011-1134-z. Epub 2011 Nov 6.</citation>
    <PMID>22057678</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 27, 2016</lastchanged_date>
  <firstreceived_date>September 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cancer</keyword>
  <keyword>Oral Cavity</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
